Arcturus Therapeutics vs Scynexis
ARCT and SCYX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARCT and SCYX compare
Arcturus Therapeutics is the larger company, worth 8.2 times as much as Scynexis ($236M against $29.0M).
Scynexis grew revenue faster over the last twelve months (490% versus −76.0% for Arcturus Therapeutics).
Scynexis keeps more of each dollar of sales as profit, with a net margin of −53.3% compared with −318% at Arcturus Therapeutics.
Scynexis scores higher on the StockData Score (13 against 9 for Arcturus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARCT | SCYX |
|---|---|---|
| Size and price | ||
| Market cap | $236M | $29.0M |
| Share price | $8.31 | $2.91 |
| Change, 1 year | 6.9% | −38.4% |
| Change, 5 years | −79.2% | −95.1% |
| Beta (5Y) | 1.97 | 1.56 |
| Employees | 111 | 18 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.0× | 1.5× (better) |
| P/B | 1.4× | 0.4× (better) |
| FCF yield | −30.8% | – |
| Fair value | $8.82 | $10.10 |
| Margin of safety | 5.8% | 71.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −76.0% | 490% (better) |
| Revenue growth, 5Y average | 53.8% | – |
| Profitability | ||
| Operating margin | −348% | −118% (better) |
| Net margin | −318% | −53.3% (better) |
| FCF margin | −248% | – |
| Return on equity | −46.3% | −18.4% (better) |
| Return on invested capital | −1084% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.88 | 9.65 (better) |
| Altman Z-score | −1.33 (better) | −5.22 |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 87.9% | 51.7% |
| Held by insiders | 8.1% | 24.8% |
| Short interest, % of float | 20.7% | 6.0% |
Go deeper
- ARCT stock overview
- ARCT income statement
- ARCT valuation and score
- SCYX stock overview
- SCYX income statement
- SCYX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.